Akums Drugs and Pharmaceuticals Limited (NSE: AKUMS | BSE: 544222)
Source: Akums Drugs and Pharmaceuticals Limited Annual Report FY 2025-26 (Fiscal Year Ended March 31, 2026) 📊 Stock Screeners
Akums Drugs and Pharmaceuticals Limited is India’s largest pharmaceutical Contract Development and Manufacturing Organisation (CDMO) by volume, delivering integrated commercialization solutions across the pharmaceutical value chain. Operating an extensive ecosystem of 14 advanced manufacturing facilities, Akums serves as an innovation and scale backbone for major pharmaceutical brand owners across India and 72 international geographies.
- Oral Solid Dosage (OSD): Annual installed capacity of 47.90 Billion units (tablets, modified-release formats, hard gelatin capsules, bilayer and trilayer tablets, tablet-in-tablet, and multiparticulates).
- Oral Liquids & Syrups: Annual installed capacity of 417.60 Million bottles across suspensions, syrups, and pediatric liquid formulations.
- Injectable & Sterile Formulations: Annual installed capacity of 767.00 Million units across small-volume parenterals, liquid ampoules, lyophilized injectables, dry powder beta-lactam vials, and ophthalmic drops.
- External & Topical Preparations: Annual installed capacity of 158.40 Million tubes across derma creams, gels, medicated ointments, and topical foams.
📋 Quick Facts / Company Snapshot: Akums Drugs and Pharmaceuticals Limited (NSE: AKUMS | BSE: 544222)
| Attribute | Disclosed Detail |
|---|---|
| Official Company Name | Akums Drugs and Pharmaceuticals Limited |
| Corporate Identity Number (CIN) | L24239DL2004PLC125888 |
| Stock Exchange Listing | National Stock Exchange of India (Symbol: AKUMS) | BSE Limited (Scrip Code: 544222) |
| Date of Incorporation | April 19, 2004 |
| Founders & Promoters | Sanjeev Jain & Sandeep Jain (Co-Founders & Managing Directors) |
| Registered Office | 304, 3rd Floor, Mohan Place, L.S.C, C-Block, Saraswati Vihar, Delhi – 110034, India |
| Corporate Headquarters | Akums House, Plot No. 131 to 133, Block-C, Mangolpuri Industrial Area, Phase-I, Delhi – 110083, India |
| Contact Phone & Email | +91-11-69041000 | cs@akums.net / investors@akums.net |
| Leadership | Sanjeev Jain (Co-Founder & MD) | Sandeep Jain (Co-Founder & MD) | Sanjay Sinha (Whole Time Director & President – Operations) |
| Key Financial Executives | Sumeet Sood (Chief Financial Officer) | Dharamvir Malik (Company Secretary & Compliance Officer) |
| Promoter Group Holding | 75.26% (Akums Master Trust: 40.79%, Sanjeev Jain: 17.21%, Sandeep Jain: 17.23%) |
| Industry / Sector | Pharmaceuticals / Contract Development and Manufacturing Organisation (CDMO) & APIs (NIC Code: 2100) |
| Total Workforce | 18,010 Total Workforce (6,455 Permanent Employees, 882 Permanent Workers, 10,673 Contractual Workers) |
| Manufacturing Network | 14 Consolidated Manufacturing Facilities (11 CDMO Formulation Plants, 3 API Plants) |
| Credit Ratings | ICRA Limited: [ICRA]AA (Stable) / [ICRA]A1+ (Reaffirmed); Commercial Paper: [ICRA]A1+ (Assigned) |
| Statutory Auditors | Walker Chandiok & Co LLP, Chartered Accountants |
| Secretarial Auditors | M/s SPG & Associates, Practising Company Secretaries |
| Cost & Internal Auditors | Balwinder & Associates (Cost Auditors) | Mahajan & Aibara LLP (Internal Auditors FY 2026-27) |
| Registrar & Share Transfer Agent | MUFG Intime India Private Limited (formerly Link Intime India Private Limited) |
🏢 The Corporate Identity: Akums Overview, Promoters & History
The Big Picture: Business Model & Core Value Proposition
Akums Drugs and Pharmaceuticals Limited is India’s largest pharmaceutical Contract Development and Manufacturing Organisation (CDMO) by volume, delivering integrated commercialization solutions across the pharmaceutical value chain. Operating an extensive ecosystem of 14 advanced manufacturing facilities, Akums serves as an innovation and scale backbone for major pharmaceutical brand owners across India and 72 international geographies. The company’s business engine spans five primary operating pillars: Formulation CDMO, Active Pharmaceutical Ingredients (API), Domestic Branded Formulations, International Branded Formulations, and Trade Generics.
The company’s core strategy is built on backward integration, specialized complex delivery systems, and aggressive international market entry. Akums manufactures formulations for 26 of the top 30 pharmaceutical enterprises in India by sales volume, maintaining customer relationships with over 1,700 active CDMO clients. By offering end-to-end commercial solutions—from pre-formulation chemistry, analytical validation, and regulatory dossier preparation to commercial-scale manufacturing—Akums enables client partners to optimize capital allocation and transition toward asset-light operational models.
- Formulation Leadership: Consolidated installed capacity of over 50.60 Billion units across oral solids, liquid orals, sterile injectables, topicals, hormones, beta-lactams, and nutraceuticals.
- Robust R&D Backbone: 4 dedicated R&D centers employing over 370 scientific personnel (including 200+ doctorates and post-graduates) driving a pipeline of 1,035+ cumulative DCGI product approvals.
- Backward Integration Strategy: 3 API production units generating critical raw materials, active ingredients, and cephalosporin intermediates to secure supply continuity.
- Global Regulatory Footprint: Facilities accredited with WHO-GMP, EU-GMP, ANVISA (Brazil), and Russian Ministry of Health GMP certifications, enabling export enablement across regulated and semi-regulated markets.
The Founders, Promoters & Their Legacy
The foundation of Akums was established in 2004 by first-generation entrepreneurs Sanjeev Jain and Sandeep Jain. Over two decades of execution, the co-founders built the enterprise into India’s premier CDMO platform, creating custom contract manufacturing infrastructure when the domestic pharmaceutical industry primarily relied on captive production facilities.
Sanjeev Jain, Co-Founder and Managing Director, brings four decades of experience in sales, marketing, corporate strategy, business development, and enterprise risk management. His leadership led to key international joint ventures, including the joint manufacturing transaction with the Government of the Republic of Zambia. Sandeep Jain, Co-Founder and Managing Director, oversees operational execution, manufacturing engineering, technology integration, and regulatory site preparedness. He has served as Chairman of the Confederation of Indian Industry (CII) Uttarakhand State Council, Chairman of the Association of Pharmaceutical Manufacturers of Uttarakhand, and Vice-Chairman of the Federation of Pharma Entrepreneurs (FOPE).
The Journey: Corporate History & Key Milestones
Incorporated on April 19, 2004, under the Companies Act, 1956, Akums commenced commercial operations in Haridwar, Uttarakhand. The group expanded its operational manufacturing cluster across Haridwar, Kotdwar (Uttarakhand), and Baddi (Himachal Pradesh), establishing dedicated dosage plants to prevent cross-contamination and support high-volume runs.
Key evolutionary milestones include:
- 2004: Incorporation of Akums Drugs and Pharmaceuticals Limited and setup of foundational formulation plants in Haridwar.
- 2010–2015: Expansion into specialized dosage forms including hormonal formulations, sterile injectables, eye drops, and nutraceutical lines; establishment of domestic marketing subsidiary Akumentis Healthcare Limited.
- 2018–2022: Backward integration through the acquisition and setup of API production units in Sundran, Chachrauli, and Barwala; securing EU-GMP certifications.
- 2024: Successful completion of initial public offering (IPO) and listing of equity shares on the National Stock Exchange of India (NSE) and BSE Limited on August 6, 2024.
- 2025–2026: Securing a €100.00 Million upfront component under a long-term European CDMO contract; initial commercial dispatches of Dapagliflozin to Switzerland; establishing a 51:49 joint venture company—Akums Healthcare (Zambia) Private Limited—with the Government of Zambia to build a USD 45.00 Million multi-dosage plant in Lusaka.
The Corporate Umbrella & Group Structure
The group operates through a parent-subsidiary structure comprising 15 direct and step-down subsidiaries, 1 limited liability partnership, 2 wholly-owned foreign subsidiaries in the UK and Malta, and 1 foreign joint venture in Zambia. Core manufacturing, marketing, and distribution responsibilities are executed through key operating entities:
- Pure and Cure Healthcare Private Limited (100% WOS): Primary formulation manufacturing arm operating state-of-the-art facilities in Haridwar and Baddi.
- Malik Lifesciences Private Limited (100% WOS): Specialized CDMO manufacturing entity producing liquid orals, ointments, and solid dosages.
- Maxcure Nutravedics Limited (100% WOS): Dedicated platform for consumer wellness, nutraceuticals, food supplements, and medicated gummies.
- Akumentis Healthcare Limited (91.50% Subsidiary): Domestic prescription branded formulation arm targeting therapy areas across gynecology, cardiology, diabetology, and gastroenterology.
- Unosource Pharma Limited (100% WOS): International brand management and export execution subsidiary supplying formulations to 72 overseas countries.
- Akums Healthcare (Zambia) Private Limited (51% JV): Foreign joint venture established with the Government of Zambia to construct a regional pharmaceutical plant in Lusaka.
⚙️ The Business Engine: Akums Segments, Brands, Products & Operations
The Core Divisions & Segment Revenue Breakdown
Akums reports five operational segments under Ind AS 108. Contract Development and Manufacturing Operations (CDMO) forms the core of the group’s business model, accounting for 79.95% of total external revenue from operations in FY 2025-26.
| Business Segment | FY 2025-26 Revenue (₹ Cr) | % Share of Total Revenue | FY 2024-25 Revenue (₹ Cr) | FY 2025-26 PBIT / Result (₹ Cr) | FY 2025-26 Segment Assets (₹ Cr) | FY 2025-26 Segment Liabilities (₹ Cr) | Latest YoY (%) |
|---|---|---|---|---|---|---|---|
| CDMO (Net External) | 3,485.20 | 79.95% | 3,207.88 | 329.03 | 3,054.40 | 1,817.71 | +8.64% |
| Domestic Branded Formulations | 446.30 | 10.25% | 433.59 | 87.24 | 77.05 | 114.61 | +2.93% |
| Active Pharmaceutical Ingredients (API) | 184.44 | 4.23% | 219.30 | -57.66 | 396.95 | 31.30 | -15.90% |
| International Branded Formulations | 143.46 | 3.29% | 142.61 | 34.23 | 92.94 | 58.42 | +0.60% |
| Trade Generics | 99.62 | 2.29% | 114.79 | -11.39 | 45.68 | 43.77 | -13.22% |
| Inter-Segment Eliminations / Corporate | 0.00 | 0.00% | 0.00 | 0.64 | 1,779.95 | 50.03 | N/M |
| TOTAL CONSOLIDATED | 4,359.02 | 100.00% | 4,118.16 | 382.10 (PBT) | 5,446.97 | 2,115.85 | +5.85% |
During FY 2025-26, the CDMO segment achieved double-digit volume growth, offsetting input cost softness in raw material API prices. Margin stability in CDMO operations was preserved by the cost-plus structure of commercial agreements, where raw material price movements are passed on to customer partners. The segment generated ₹466.93 Crores in segment result before depreciation (EBITDA), compared to ₹453.89 Crores in FY 2024-25.
The Product & Service Catalog
Akums maintains a portfolio of over 24,000 active commercial SKUs spanning diverse dosage formats. Key manufacturing capabilities include:
- Oral Solid Dosage (OSD): Annual installed capacity of 47.90 Billion units (tablets, modified-release formats, hard gelatin capsules, bilayer and trilayer tablets, tablet-in-tablet, and multiparticulates).
- Oral Liquids & Syrups: Annual installed capacity of 417.60 Million bottles across suspensions, syrups, and pediatric liquid formulations.
- Injectable & Sterile Formulations: Annual installed capacity of 767.00 Million units across small-volume parenterals, liquid ampoules, lyophilized injectables, dry powder beta-lactam vials, and ophthalmic drops.
- External & Topical Preparations: Annual installed capacity of 158.40 Million tubes across derma creams, gels, medicated ointments, and topical foams.
- Specialized API Production: Annual capacity of 737.00 Metric Tonnes producing Cefuroxime Axetil, Cefpodoxime Proxetil, Ceftriaxone Sodium Sterile, Cefixime Trihydrate, Montelukast Sodium, Atorvastatin Calcium, and Avibactam Sodium.
- Customer Concentration Disclosure: In compliance with Ind AS 108 disclosures, no single external customer accounts for 10% or more of total consolidated revenue.
The Names You Know: Key Brands & Flagship Portfolio
| Brand / Product Name | Category / Business Segment | Target Market & Key Positioning |
|---|---|---|
| Akumentis Portfolio | Domestic Branded Formulations | Prescription therapies across gynecology, cardiology, gastroenterology, and diabetology sold via medical representatives. |
| Maxcure Nutraceuticals | Consumer Wellness & OTC | Medicated gummies, chewable vitamins, soft chews, dietary supplements, and lifestyle wellness platforms. |
| Triple Hair Technology Platform | Dermatology / License Partnership | Patented topical prescription solution for alopecia, licensed exclusively from Triple Hair (Canada) for the Indian market. |
| Caregen Peptide Range | Dermo-Cosmetics & Specialty Therapy | Advanced peptide-based dermatological solutions marketed in India via an exclusive partnership with Caregen (South Korea). |
| Unosource Global Generics | International Branded Formulations | Finished oral solid, liquid, and injectable generic formulations supplied across 72 semi-regulated and emerging markets. |
Mapping the Domestic & Global Reach (India vs. Exports)
| Geographic Region | FY 2025-26 Revenue (₹ Cr) | % Share of Total Revenue | FY 2024-25 Revenue (₹ Cr) | Key Markets & Regions Served | Latest YoY (%) |
|---|---|---|---|---|---|
| Domestic (India) | 4,167.22 | 95.60% | 3,936.96 | Pan-India distribution across 28 states & 8 UTs serving top pharma firms, hospitals, and Jan Aushadhi. | +5.85% |
| International (Exports) | 191.80 | 4.40% | 181.20 | 72 countries across Europe (Switzerland), Latin America (Brazil-ANVISA), CIS (Russia), Africa (Zambia), and SEA. | +5.85% |
| TOTAL REVENUE FROM OPERATIONS | 4,359.02 | 100.00% | 4,118.16 | Global CDMO & Formulation Network | +5.85% |
The Brick & Mortar Footprint: Manufacturing Plants, R&D & Offices
Akums manages 14 manufacturing facilities located in key industrial clusters:
- Haridwar Cluster (Uttarakhand): 8 formulation manufacturing plants (Plant I, II, III, IV, VI, VII, X, and Pure & Cure Haridwar facility) specializing in oral solids, oral liquids, sterile injectables, beta-lactams, and hormonal blocks.
- Kotdwar Unit (Uttarakhand): Plant VIII dedicated to large-scale oral solid formulations and high-volume packaging.
- Baddi Cluster (Himachal Pradesh): 2 formulation facilities (Plant IX and Plant XI / Pure & Cure Baddi-2) producing multi-dosage formulations, nutraceuticals, and soft chews.
- API Manufacturing Cluster: 3 API units situated in Sundran (Punjab – ALS-1), Chachrauli (Punjab – ALS-2), and Barwala (Haryana – ALS-3).
- Research & Development Hubs: 4 R&D facilities located in Haridwar, Mumbai, and Barwala. The facilities feature DSIR accreditation and house 370+ scientific staff.
📊 The Financial Health: Akums Financial Statements & Numbers Simplified
Multi-Year Financial Highlights
| Metric (₹ in Crores) | FY 2025-26 | FY 2024-25 | FY 2023-24 | Latest YoY (%) |
|---|---|---|---|---|
| Revenue from Operations | 4,359.02 | 4,118.16 | 4,170.30 | +5.85% |
| Total Income | 4,487.74 | 4,170.28 | 4,212.20 | +7.61% |
| Adjusted EBITDA | 522.03 | 460.61 | 480.80 | +13.33% |
| Adjusted EBITDA Margin (%) | 12.00% | 11.20% | 11.50% | – |
| Adjusted PAT | 276.00 | 217.20 | 246.60 | +27.07% |
| Net Profit for the Year (Reported PAT) | 256.40 | 343.78 | 14.26 | -25.42% |
| Net Cash Generated from Operating Activities | 1,181.20 | 465.20 | 27.60 | +153.91% |
| Total Equity (Net Worth) | 3,331.12 | 3,063.61 | 691.87 | +8.73% |
| Return on Equity (ROE %) | 7.70% | 11.22% | – | – |
| Return on Capital Employed (ROCE %) | 8.44% | 9.54% | – | – |
Earnings, Expenses, & Take-Home Profits (Consolidated Profit & Loss)
| Statement of Profit and Loss (₹ in Crores) | FY 2025-26 | FY 2024-25 | Latest YoY (%) |
|---|---|---|---|
| Revenue from Operations | 4,359.02 | 4,118.16 | +5.85% |
| Other Income | 128.73 | 52.12 | +146.99% |
| TOTAL INCOME | 4,487.74 | 4,170.28 | +7.61% |
| Cost of Materials Consumed | 2,298.68 | 2,253.61 | +2.00% |
| Purchase of Stock-in-Trade | 201.00 | 181.47 | +10.76% |
| Changes in Inventories of Finished Goods, Stock-in-Trade and WIP | 13.84 | -1.65 | N/M |
| Employee Benefits Expense | 753.82 | 715.82 | +5.31% |
| Finance Costs | 94.07 | 34.60 | +171.88% |
| Depreciation and Amortisation Expense | 154.55 | 153.45 | +0.72% |
| Fair Value Changes to Financial Instruments | 0.00 | -3.87 | -100.00% |
| Other Expenses | 569.65 | 508.29 | +12.07% |
| TOTAL EXPENSES | 4,085.62 | 3,841.72 | +6.35% |
| EBITDA | 522.03 | 460.61 | +13.33% |
| Operating Profit / EBIT | 367.48 | 307.17 | +19.63% |
| Profit Before Exceptional Items and Tax | 402.13 | 328.56 | +22.39% |
| Exceptional Items | 20.02 | -16.70 | N/M |
| Profit Before Tax (PBT) | 382.10 | 345.25 | +10.67% |
| Tax Expense: Current Tax (including earlier years) | 89.83 | 79.75 | +12.64% |
| Tax Expense: Deferred Tax (including earlier years) | 35.88 | -78.27 | N/M |
| Total Tax Expense | 125.70 | 1.48 | +8393.24% |
| Profit for the Year (PAT) | 256.40 | 343.78 | -25.42% |
| Other Comprehensive Income (net of tax) | 0.92 | -1.10 | N/M |
| Total Comprehensive Income for the Year | 257.32 | 342.68 | -24.91% |
Assets, Borrowings, & Net Worth (Consolidated Balance Sheet)
| Balance Sheet (₹ in Crores) | As at March 31, 2026 | As at March 31, 2025 | Latest YoY (%) |
|---|---|---|---|
| NON-CURRENT ASSETS | |||
| Property, Plant and Equipment | 1,279.41 | 1,228.69 | +4.13% |
| Right-of-Use Assets | 168.85 | 161.49 | +4.56% |
| Capital Work-in-Progress | 176.66 | 159.62 | +10.68% |
| Goodwill | 2.06 | 2.06 | 0.00% |
| Other Intangible Assets & Development | 6.21 | 8.30 | -25.18% |
| Non-Current Financial Assets (Investments & Others) | 29.47 | 33.70 | -12.55% |
| Non-Current Tax Assets (net) | 17.95 | 12.31 | +45.82% |
| Deferred Tax Assets | 170.89 | 208.07 | -17.87% |
| Other Non-Current Assets | 35.60 | 24.60 | +44.72% |
| Total Non-Current Assets | 1,887.11 | 1,838.83 | +2.63% |
| CURRENT ASSETS | |||
| Inventories | 755.71 | 680.93 | +10.98% |
| Trade Receivables | 796.56 | 770.30 | +3.41% |
| Cash and Cash Equivalents | 386.01 | 101.19 | +281.47% |
| Bank Balances other than Cash and Cash Equivalents | 1,294.59 | 475.26 | +172.40% |
| Other Current Financial Assets | 29.57 | 48.13 | -38.56% |
| Other Current Assets | 297.41 | 198.80 | +49.60% |
| Total Current Assets | 3,559.86 | 2,274.61 | +56.50% |
| TOTAL ASSETS | 5,446.97 | 4,113.44 | +32.42% |
| EQUITY AND LIABILITIES | |||
| Equity Share Capital | 30.62 | 30.62 | 0.00% |
| Other Equity | 3,282.73 | 3,016.39 | +8.83% |
| Non-Controlling Interests | 17.77 | 16.60 | +7.05% |
| Total Equity (Net Worth) | 3,331.12 | 3,063.61 | +8.73% |
| NON-CURRENT LIABILITIES | |||
| Non-Current Lease Liabilities | 76.84 | 67.33 | +14.12% |
| Other Non-Current Financial Liabilities & Provisions | 85.73 | 70.14 | +22.23% |
| Deferred Tax Liabilities | 17.71 | 18.62 | -4.89% |
| Other Non-Current Liabilities (European Contract Upfront) | 840.81 | 0.00 | N/M |
| Total Non-Current Liabilities | 1,021.09 | 156.08 | +554.21% |
| CURRENT LIABILITIES | |||
| Current Borrowings | 72.95 | 13.66 | +434.04% |
| Current Lease Liabilities | 7.63 | 7.23 | +5.53% |
| Trade Payables (MSME: ₹87.98 Cr | Others: ₹514.18 Cr) | 602.16 | 642.78 | -6.32% |
| Other Current Financial Liabilities | 133.65 | 133.33 | +0.24% |
| Other Current Liabilities | 204.02 | 39.14 | +421.26% |
| Provisions & Current Tax Liabilities (net) | 74.35 | 57.61 | +29.06% |
| Total Current Liabilities | 1,094.76 | 893.75 | +22.49% |
| Total Liabilities (Excluding Equity) | 2,115.85 | 1,049.83 | +101.54% |
| TOTAL EQUITY AND LIABILITIES | 5,446.97 | 4,113.44 | +32.42% |
Working Capital Cycle & Schedule III Statutory Ratio Explanations
| Financial Ratio | FY 2025-26 | FY 2024-25 | YoY Change % / Reason for Variance > 25% |
|---|---|---|---|
| Fixed Asset Turnover Ratio | 3.0x | 2.9x | +3.4% (Improved asset utilization with higher revenue growth) |
| Debt-Equity Ratio | 0.02x | 0.00x | Debt levels remained insignificant compared to net worth |
| Return on Equity (ROE %) | 7.70% | 11.20% | -31.25% (Lower reported PAT and expanded post-IPO equity base) |
| Return on Capital Employed (ROCE %) | 21.30% | 12.30% | +73.17% (Higher operating profit and reduced net capital employed) |
| EBITDA Margin (%) | 12.00% | 11.20% | +71 bps (Improved product mix and operational cost discipline) |
| PAT Margin (%) | 5.70% | 8.20% | -250 bps (Lower reported profit after tax led to PAT margin contraction) |
| Debtors Days | 67 days | 68 days | -1 day (Stable trade receivables collection efficiency) |
| Inventory Days | 105 days | 99 days | +6 days (Strategic stocking of raw materials and new SKU launches) |
| Creditors Days | 71 days | 80 days | -9 days (Faster vendor payables processing) |
| Net Working Capital Days | 110 days | 91 days | +19 days (Driven by inventory buildup for international dispatches) |
Cash Flow: Tracking the Money Movement
| Statement of Cash Flows (₹ in Crores) | FY 2025-26 | FY 2024-25 | Latest YoY (%) |
|---|---|---|---|
| Net Cash Generated from Operating Activities (A) | 1,181.20 | 465.20 | +153.91% |
| Purchase of Property, Plant & Equipment & Intangibles (CapEx) | 230.53 | 272.31 | -15.34% |
| Proceeds from Sale of Property, Plant and Equipment | 7.75 | 8.55 | -9.36% |
| Investments in Deposits with Original Maturity > 3 Months (net) | -746.12 | -309.06 | +141.42% |
| Interest Received & NCI Consideration | 38.63 | 24.99 | +54.58% |
| Net Cash Used in Investing Activities (B) | -930.27 | -547.84 | +69.81% |
| Proceeds from Issue of Shares (net of issue expenses) | 0.00 | 637.37 | -100.00% |
| Proceeds from / (Repayment of) Borrowings (net) | 59.30 | -477.90 | N/M |
| Payment of Lease Liabilities & Interest Costs | -25.42 | -86.68 | -70.67% |
| Dividends Paid on Equity Shares | 0.00 | 0.00 | N/M |
| Net Cash Generated from Financing Activities (C) | 33.88 | 72.79 | -53.46% |
| Net Increase / (Decrease) in Cash & Cash Equivalents (A+B+C) | 284.81 | -9.86 | N/M |
| Cash and Cash Equivalents at Beginning of Year | 101.19 | 111.05 | -8.88% |
| Cash and Cash Equivalents at End of Year | 386.01 | 101.19 | +281.47% |
Funding the Future: CapEx, CWIP, R&D Intensity & Net Foreign Exchange
Akums deployed total capital expenditure of ₹222.00 Crores in FY 2025-26 toward manufacturing upgrades and regulatory compliance. The largest deployment was directed to the Akums-3 Haridwar facility, absorbing ₹51.91 Crores to install advanced equipment. Additional CapEx investments were allocated to Pure & Cure Haridwar (₹10.75 Crores), Pure & Cure Baddi-2 (₹4.47 Crores), Akums-9 (₹4.62 Crores), Upadhrish facility (₹4.29 Crores), Plant-2 EU project (₹2.63 Crores), Akums-2 (₹2.33 Crores), and Akums-1 (₹1.20 Crores).
R&D expenditure reached ₹139.70 Crores in FY 2025-26 (representing 3.20% of total income), compared to ₹112.00 Crores in FY 2024-25 (2.60% of total income). Total foreign exchange earnings from exports stood at ₹191.80 Crores, against foreign exchange outgo for raw materials, capital goods, and professional fees.
👥 Power & Control: Akums Governance, Leadership & Shareholding Pattern
The Brain Trust: Board of Directors & Key Managerial Personnel (KMP)
| Name of Director / KMP | Designation / Role | DIN | Category |
|---|---|---|---|
| Sanjeev Jain | Co-Founder & Managing Director | 00323433 | Executive Director (Promoter) |
| Sandeep Jain | Co-Founder & Managing Director | 00323476 | Executive Director (Promoter) |
| Sanjay Sinha | Whole-Time Director & President – Operations | 03627342 | Executive Director |
| Kewal Handa | Independent Director (Chairman Audit Committee) | 00056826 | Non-Executive Independent Director |
| Matangi Gowrishankar | Independent Director (Chairperson NRC) | 01518137 | Non-Executive Independent Director |
| Satwinder Singh | Independent Director (Chairman Stakeholders Relationship) | 00164903 | Non-Executive Independent Director |
| Anil Amin | Independent Director (Appointed June 4, 2025) | 10594012 | Non-Executive Independent Director |
| Sunil Kumar Thakur | Non-Executive Director | 03266370 | Non-Executive Non-Independent Director |
| Sumeet Sood | Chief Financial Officer (CFO) | KMP | Key Managerial Personnel |
| Dharamvir Malik | Company Secretary & Compliance Officer | KMP | Key Managerial Personnel |
Who Owns the Stock? Shareholding Pattern
| Category of Shareholder | Number of Equity Shares Held | % of Total Issued Equity Shares |
|---|---|---|
| Promoter & Promoter Group | 11,84,55,480 | 75.26% |
| Mutual Funds | 1,72,30,213 | 10.95% |
| Alternate Investment Funds (AIFs) | 44,17,801 | 2.81% |
| Foreign Institutional / Portfolio Investors (FIIs/FPIs) | 21,59,906 | 1.37% |
| Insurance Companies | 9,36,619 | 0.60% |
| Non-Promoter Non-Public Shareholding (ESOP Trust) | 42,91,930 | 2.73% |
| Bodies Corporate | 7,89,348 | 0.50% |
| Non-Resident Indians (NRIs) | 2,71,853 | 0.17% |
| Trusts, LLPs, HUF & Clearing Members | 4,33,294 | 0.28% |
| Indian Public & Retail Investors | 84,07,544 | 5.34% |
| TOTAL ISSUED EQUITY SHARES | 15,73,93,988 | 100.00% |
🗺️ The Corporate Family Tree: Group Structure, Ratings & Contingent Liabilities
Subsidiaries, Associates, & Joint Ventures (Form AOC-1)
| Name of Entity | Relationship & Country | % Holding | FY 2025-26 Turnover (₹ Cr) | FY 2025-26 Profit / Loss After Tax (₹ Cr) |
|---|---|---|---|---|
| Pure and Cure Healthcare Private Limited | Wholly Owned Subsidiary (India) | 100.00% | 1,738.38 | 100.11 |
| Akumentis Healthcare Limited | Subsidiary (India) | 91.50% | 446.30 | 13.82 |
| Malik Lifesciences Private Limited | Wholly Owned Subsidiary (India) | 100.00% | 370.05 | 28.48 |
| Akums Healthcare Limited | Wholly Owned Subsidiary (India) | 100.00% | 293.73 | |
| Maxcure Nutravedics Limited | Wholly Owned Subsidiary (India) | 100.00% | 178.80 | 24.80 |
| Unosource Pharma Limited | Wholly Owned Subsidiary (India) | 100.00% | 143.46 | 23.20 |
| Qualymed Pharma Private Limited | Wholly Owned Subsidiary (India) | 100.00% | 51.86 | -11.77 |
| Sarvagunaushdhi Private Limited | Wholly Owned Subsidiary (India) | 100.00% | 42.23 | -11.06 |
| Upadhrish Researchem LLP | Subsidiary LLP (India) | 100.00% | 37.99 | 5.01 |
| Plenteous Pharmaceuticals Limited | Wholly Owned Subsidiary (India) | 100.00% | 35.51 | -10.51 |
| Nicholas Healthcare Limited | Wholly Owned Subsidiary (India) | 100.00% | 30.84 | 18.49 |
| Medibox Pharma Private Limited | Step-Down Subsidiary (India) | 100.00% | 9.50 | -21.59 |
| Akums Healthcare UK Limited | Foreign WOS (United Kingdom) | 100.00% | 0.00 | -0.13 |
| Akums Healthcare Malta Private Limited | Foreign WOS (Malta) | 100.00% | 0.00 | 0.00 |
| Akums Healthcare (Zambia) Private Limited | Foreign Joint Venture (Zambia) | 51.00% | 0.00 | 0.00 |
Strategic Investments, Credit Ratings, Banking Consortium & Contingent Liabilities
In April 2026, ICRA Limited reaffirmed the group’s long-term and short-term credit ratings at [ICRA]AA (Stable) / [ICRA]A1+ for working capital limits and assigned an [ICRA]A1+ rating for its proposed commercial paper program.
Contingent liabilities and off-balance-sheet commitments as of March 31, 2026, comprise:
- Taxation Disputes & Demands: Outstanding tax matters under appeal with judicial authorities. Management, based on advice from tax counsel, assesses that no material loss will arise.
- Capital Commitments: Estimated contracts remaining to be executed on capital account and not provided for (net of advances) stood at ₹80.45 Crores (compared to ₹73.35 Crores as of March 31, 2025).
- Legal & Supplier Claims: Pending claims including a product defect supplier claim of ₹0.20 Crore and customer counterclaims of ₹0.08 Crore undergoing legal review.
🎯 The Strategic Outlook: Competitive Moats, Risks, Growth Plans & FAQs
Competitive Advantages & Economic Moats
Akums maintains competitive moats across the Indian CDMO landscape:
- Unrivaled Scale & Footprint: 14 manufacturing facilities delivering 50.60 Billion dosage units annually across 24,000+ SKUs.
- Client Integration: Commercial relationships with 26 of India’s top 30 pharmaceutical enterprises by sales. Long-term customer stickiness is supported by technology transfers, regulatory filings, and dedicated manufacturing blocks.
- R&D Pipeline & Regulatory Capital: 1,035+ DCGI approvals, 129+ patent filings, and 14 granted patents. Integrated pre-formulation chemistry, solubility profiling, and rapid scale-up frameworks reduce time-to-market for partner clients.
- EU-GMP & Global Certifications: EU-GMP accredited facilities, ANVISA approval for Plant 3, and GMP certification from Russia (Plant 4).
What Could Go Wrong? Key Challenges & Business Risks
Key business, regulatory, and operational risks identified by management include:
- Raw Material & API Volatility: Price softness or supply disruptions in key active ingredients may impact revenue value realizations, although cost-plus contract mechanisms help buffer margin impacts.
- Strict Regulatory Audits: Compliance lapses during inspections by CDSCO, US FDA, or European regulators could lead to site observations or supply disruptions.
- Under-Utilization of Expanded Capacities: Consolidated CDMO capacity utilization stood at 42.9% in FY 2025-26. Scaling up order inflows across newly commissioned oncology, steroid, and oral solid lines remains essential for operating leverage.
- Cybersecurity & IT Data Privacy: Digital integration across enterprise systems (SAP ERP, LIMS, e-QMS) exposes operations to cyber threats and compliance requirements under the Digital Personal Data Protection Act, 2023.
The Next Chapter: Growth, Order Pipeline & CapEx Initiatives
Akums’ growth strategy focuses on expanding its presence in regulated export markets, deepening API backward integration, and scaling up complex formulations:
- European CDMO Expansion: Following an audit of Plant 2 and initial commercial supplies of Dapagliflozin to Switzerland, Akums plans to dispatch Rivaroxaban to European territories, supported by a pipeline of 50 dossiers.
- African Joint Venture Deployment: Constructing a multi-dosage manufacturing facility in Lusaka, Zambia (USD 45.00 Million project cost), targeting medicine supply contracts worth USD 50.00 Million over the next two years.
- High-Value Differentiated Dossiers: Accelerating development of triple-layer tablets, oral osmotic pump tablets, pulmonary inhalation formats, topical foams, and lyophilized parenterals.
- Operational Productivity: Leveraging digital automation (LIMS, e-QMS, warehouse QR-tracking) to drive shop-floor productivity gains and asset utilization beyond 50%.
The Verdict: Strategic Outlook & Conclusion
With consolidated revenue from operations reaching ₹4,359.02 Crores, operating cash flows expanding to ₹1,181.20 Crores, and a net cash balance exceeding ₹1,648.50 Crores, Akums maintains a solid balance sheet to fund its expansion plans. Managed leverage, disciplined working capital management, and strategic investments in European and African markets position Akums to strengthen its market share in global pharmaceutical CDMO markets.
Frequently Asked Questions (FAQs) About Akums
Q1: What does Akums Drugs and Pharmaceuticals Limited manufacture?
Akums is a Contract Development and Manufacturing Organisation (CDMO) producing oral solid tablets, capsules, liquid syrups, sterile injectables, eye drops, ointments, hormonal tablets, nutraceuticals, and Active Pharmaceutical Ingredients (APIs) across 24,000+ commercial SKUs.
Q2: What were Akums’ revenue and net profit in FY 2025-26?
In FY 2025-26, Akums reported total revenue from operations of ₹4,359.02 Crores (up 5.85% YoY), total income of ₹4,487.74 Crores, Adjusted EBITDA of ₹522.03 Crores, and a net profit after tax (PAT) of ₹256.40 Crores.
Q3: Who are the main promoters and executive leaders of Akums?
The company was founded and is led by Sanjeev Jain and Sandeep Jain, who serve as Co-Founders and Managing Directors. Executive operations are further managed by Sanjay Sinha (Whole Time Director & President – Operations) and Sumeet Sood (Chief Financial Officer).
Q4: Where are Akums’ manufacturing facilities and R&D hubs located?
Akums operates 14 consolidated manufacturing facilities situated in Haridwar and Kotdwar (Uttarakhand), Baddi (Himachal Pradesh), Sundran and Chachrauli (Punjab), and Barwala (Haryana), complemented by 4 R&D centers in Haridwar, Mumbai, and Barwala.
Q5: What is Akums’ debt profile and credit rating?
Akums maintains a conservative balance sheet with a total net cash position exceeding ₹1,648.50 Crores (cash, bank balances, and liquid deposits minus borrowings). Its bank facilities are rated [ICRA]AA (Stable) / [ICRA]A1+ by ICRA Limited.
Note: Financial ratios, margins, YoY growth percentages, and % revenue shares are calculated by IndianCompanies.in based on disclosed Ind AS financial statements.
Official Site: https://www.akums.in